Mark F. de Groot

CEO @Pattern Immunotx

Pattern Pharma is a North American immunotherapy company focused on harnessing the innate immune system to combat cancer and infectious disease. Pattern’s lead product, P2PAR-100, is a Toll-like receptor 4 (TLR4) agonist and has been shown to be a potent immune-potentiator with broad potential applicability to oncology indications with high unmet need. P2PAR-100 has demonstrated preclinical synergy with immune checkpoint inhibition and other immunotherapies. The mechanism of action of P2PAR-100 involves the binding of the TLRs found on the surface of innate immune cells, principally TLR4 and also TLR1/2 and TLR2/6. P2PAR-100 induces the activation of dendritic cells (“DC”) and macrophages, which in turn causes the production of pro-inflammatory cytokines and the induction of anti-tumor, anti-bacterial and anti-viral effector mechanisms. In addition, activated DCs enhance Natural Killer (“NK”) cells’ effector functions. With its deep expertise in innate immunity and TLRs, Pattern’s focus is on overcoming the limitations and challenges faced by current immuno-oncology therapies.